Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Arkansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 21 | 931 | 29% |
| 2020 | 16 | 810 | 32% |
| 2021 | 21 | 891 | 37% |
| 2022 | 22 | 1,064 | 40% |
| 2023 | 24 | 1,180 | 46% |
| 2024 | 24 | 1,335 | 49% |
| 2025 from claims | – | 1,707 1,566–1,806 | 50% |
| 2026 forecast | – | 1,856 1,633–2,141 | 51% |
| 2027 forecast | – | 2,018 1,725–2,404 | 51% |
| 2028 forecast | – | 2,193 1,830–2,686 | 52% |
| 2029 forecast | – | 2,384 1,947–2,989 | 53% |
| 2030 forecast | – | 2,590 2,075–3,319 | 53% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 80% of the cases CMS names in Arkansas; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 61% inpatient hospital, 39% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~1,900 | ~1,100 | ~720 |
| 2027 · ~2,000 | ~1,200 | ~770 |
| 2028 · ~2,200 | ~1,400 | ~830 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 38% (39% in 2025), inpatient hospital about 62% (61% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 310 | 13,955+10%/yr | +10%/yr | 5.3 | 38% | 26,400 in 2030+11%/yr |
| Texas | 217 | 9,542+12%/yr | +12%/yr | 3.8 | 18% | 18,100 in 2030+11%/yr |
| South Carolina | 71 | 3,614+14%/yr | +14%/yr | 4.7 | 11% | 6,460 in 2030+10%/yr |
| Virginia | 85 | 3,380+18%/yr | +18%/yr | 2.9 | 19% | 6,100 in 2030+10%/yr |
| Tennessee | 70 | 2,864+9.6%/yr | +9.6%/yr | 3.5 | 3% | 5,150 in 2030+10%/yr |
| Georgia | 70 | 2,787+8.8%/yr | +8.8%/yr | 2.8 | 7% | 5,510 in 2030+12%/yr |
| North Carolina | 76 | 2,760+8.6%/yr | +8.6%/yr | 2.4 | 7% | 4,660 in 2030+9.1%/yr |
| Oklahoma | 50 | 1,926+8.2%/yr | +8.2%/yr | 3.6 | 8% | 3,560 in 2030+11%/yr |
| Maryland | 56 | 1,696+8.1%/yr | +8.1%/yr | 1.8 | 35% | 3,080 in 2030+10%/yr |
| Mississippi | 37 | 1,533+9.3%/yr | +9.3%/yr | 3.6 | 28% | 2,480 in 2030+8.3%/yr |
| Alabama | 39 | 1,517+9.2%/yr | +9.2%/yr | 2.9 | 6% | 2,190 in 2030+6.3%/yr |
| Louisiana | 39 | 1,487+8.4%/yr | +8.4%/yr | 3.1 | 11% | 2,580 in 2030+9.6%/yr |
| Kentucky | 42 | 1,148+5.9%/yr | +5.9%/yr | 2.2 | 0% | 2,100 in 2030+11%/yr |
| West Virginia | 16 | 642+15%/yr | +15%/yr | 2.6 | 0% | 980 in 2030+7.4%/yr |
| Delaware | 17 | 625+4.5%/yr | +4.5%/yr | 3.3 | 31% | 810 in 2030+4.3%/yr |
| District of Columbia | 8 | 352+11%/yr | +11%/yr | 5.1 | 43% | 630 in 2030+10%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 40 | 2,434−5.8%/yr | −5.8%/yr | 6.71.2× | 0% | 2,160 in 2030−1.9%/yr |
| EP ablation | 15 | 1,494+3.9%/yr | +3.9%/yr | 3.40.9× | 0% | 2,460 in 2030+8.7%/yr |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Arkansas · Every state · Compare with Florida
Boston Scientific leads with 84% of company spending on these surgeons in 2025, +16 pts on 2024.
In 2025, 4 companies reported engagement with Arkansas’s surgeons worth $79K in consulting, speaking, meals and travel tied to these products, about $3,289 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.